Our mission is to help people see more clearly and improve their quality of life.

Our technology is clinically proven to improve vision across a variety of vision conditions and is FDA-cleared for amblyopia over age 9. RevitalVision enhances the brain's visual processing, enabling significant vision improvements beyond standard eye care, truly making a difference

Meet the Team

Yair Yahav
Founder & CEO
Yogev Shamay
Co-founder & CTO
Yuval Ron-Ruhama
COO
Charles Morris
General Manager –N. America
Yonina Thee
Clinical Specialist
Inbal Sasson
Clinical Research Manager
Shlomo Abramson
Clinical Service Manager
Rona Erlich
Marketing Director

Board

Yariv Baron
Director
Dr. Shulamit Hadi
Director
Alon Reshef
Director & Shareholder
Simon Kan
Director

Advisory Board

Amir Belson, M.D.
Advisory Board
Prof. Richard W. Hertle (MD)
Scientific & Clinical Advisor
Prof. Ramesh

Kekunnaya (MD)
Scientific & Clinical Advisor
Dr. Sarah Maling (MD)
Advisory Board
Mike Turner
Advisory Board
Prof. Yair Morad (MD)
Scientific & Clinical Advisor

Latest News and Events

News icon

April 2024

Improving Vision in Congenital Nystagmus – Pivotal RCT Results – AAPOS 2024

During the scientific program at AAPOS 2024 in Boston, Dr. Idan Hecht presented the groundbreaking findings from a prospective randomized controlled trial evaluating the efficacy of RevitalVision in improving vision in Congenital Nystagmus patients. the study demonstrated statistically significant improvement in distance and near BCVA, and significant improvement in stereo and binocular functions, offering new hope for nystagmus patients, lacking alternative solutions to improve vision.

Watch presentation
News icon

March 2024

RevitalVision Post Crosslinking Surgery Study Won the Best ASCRS Scientific Poster Award

RevitalVision’s study on post crosslinking surgery patients won the best scientific poster award at ASCRS 2024, and was selected for a live presentation.

This prospective, controlled randomized study evaluated the efficacy of RevitalVision’s vision-training software- program in improving best corrected vision in stable keratoconus patients post crosslinking surgery, and showed remarkable clinical outcomes!

The results demonstrated significant improvement in vision, with a mean improvement of 2.5 VA lines, as well as improvements in contrast sensitivity function (CSF) among crosslinked keratoconus patients who received RevitalVision treatment.

We thank Prof. Lional Raj, Prof. David Heber and the rest of Dr.Agarwal’s Eye Hospital Research team for their awarded work!

Read the full abstract
News icon

Feb 2024

AECOS (American-European Congress of Ophthalmic Surgery)

RevitalVision’s CEO, Yair Yahav, participated in the 2024 AECOS innovation forum, which featured eight top industry innovations. The forum was moderated by Mr. William Link, PhD.

 

News icon

April 2023

AAPOS 23 annual meeting- presenting poster with mid term study results

During the 48th annual meeting of the American Association for Pediatric Ophthalmology and Strabismus (AAPOS 23), Dr. Sigal Zmujack’s presented the mid-term results of two new controlled randomized studies evaluating RevitalVision’s efficacy in improving vision in nystagmus and amblyopia patients aged 9-55, which both showed significant anti-suppression effects.

Download the poster
News icon

January 2023

Narayana Nethralaya Eye Foundation – What & how does my child see Conference

RevitalVision CEO Yair Yahav was a guest speaker at the Narayana Nethralaya Eye Foundation symposium on Amblyopia, Binocular Vision, Cortical Visual Impairment, and Low Vision.

He presented a scientific & clinical review on Optimizing Cortical Visual Functions with RevitalVision.

Watch the full presentation

News icon

January 2023

A new published study on RevitalVision treatment

This independent study, which was published in Vision Development and Rehabilitation: COVD’s Digital Journal, evaluated the efficacy of RevitalVision’s perceptual-based vision training program, in improving visual acuity in adult amblyopic individuals beyond occlusion.

Read the full publication (p.260)
1 2 3 4 6